Pralsetinib, a selective inhibitor of the RET receptor tyrosine kinase, was evaluated in the ARROW trial (phase 1/2, NCT03037385) with 29 patients harboring RET fusion-positive solid tumors, including three patients with CCA. Here, NTRK1 is linked to cholangiocarcinoma.